These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 78206-0182
Last updated: February 13, 2026
What is NDC 78206-0182?
NDC 78206-0182 is the drug Cenobamate, marketed under the brand name Xcopri. It is indicated for the treatment of focal seizures in adults and approved by the FDA in 2019. It is a novel anti-epileptic with a unique mechanism of action targeting voltage-gated sodium channels.
Market Overview
Market Size and Penetration
The global epilepsy drug market was valued at approximately $4.8 billion in 2022.
Xcopri accounted for an estimated 4% of the market in 2022, reflecting its recent entry and niche positioning.
The U.S. represents roughly 60% of the total epilepsy therapeutics market, which is worth approximately $2.9 billion.
Competitive Landscape
Leading competitors include Keppra (levetiracetam), Tegretol (carbamazepine), and Vimpat (lacosamide).
Xcopri's market share is constrained by the presence of established therapies but benefits from its novel mechanism and FDA approval for a broad patient population.
Key Market Drivers
Increasing prevalence of epilepsy, projected to reach 3.4 million in the U.S. by 2030 (per CDC).
Expanding indication for focal seizures.
Growing physician acceptance of novel anti-epileptics with improved efficacy and tolerability.
Market Barriers
High drug acquisition costs (list prices >$10,000/month).
Limited long-term real-world data.
Competitive pressure from generics for older therapies.
Pricing Analysis
Current Pricing
Wholesale acquisition cost (WAC) for Xcopri is approximately $10,200 per month for a typical dose.
Insurance reimbursement varies, influenced by formulary status, prior authorization, and patient co-pays.
Pricing Trends
Initial launch prices positioned Xcopri as a premium therapy.
Discounting and rebates are common; net prices potentially 15-25% lower than WAC.
Price erosion expected over time as competition and biosimilar or generic entries develop.
Cost Comparisons
Drug
WAC per month
Indicated use
Years on Market
Xcopri (NDC 78206-0182)
~$10,200
Focal seizures in adults
Since 2019
Keppra
~$500–$600
Multiple seizure types
Since 2000
Tegretol
~$350–$400
Tonic-clonic and focal epilepsies
Since 1960s
Lacosamide (Vimpat)
~$2,000
Focal seizures
Since 2009
Reimbursement landscape
Insurance plans require prior authorization for Xcopri.
Cost-effectiveness analyses suggest that despite high costs, Xcopri's improved tolerability may drive utilization.
Price Projections
Short-term (1–2 years)
Prices are expected to stabilize at current levels given high initial pricing and limited competition.
Reimbursement adjustments could reduce net prices by 20%.
Medium-term (3–5 years)
Entry of generics expected by 2025–2026 could reduce prices by ~50–60%.
AWS (average wholesale prices) could fall to approximately $4,000–$5,000 per month with generic competition.
Long-term (5+ years)
Market entry of biosimilars and emerging competitors could lead to further price reductions.
Price erosion of 70–80% is possible in a five-year horizon, aligning Xcopri with older therapies in terms of cost.
Strategic Opportunities and Risks
Opportunities
Expansion into additional indications such as generalized seizures.
Formulary inclusion in more insurance plans through evidence of clinical benefit.
Combination therapies providing superior efficacy for refractory epilepsy.
Risks
Arrival of cheaper generics or biosimilars.
Pricing regulations or policy changes affecting pricing strategies.
Slow adoption driven by clinician familiarity with traditional therapies.
Key Takeaways
NDC 78206-0182 (Xcopri) is a high-cost, recently launched drug with a focused market niche.
Short-term prices remain stable, but long-term trends point toward significant price reductions from generic entry.
Market growth depends on expanding indications, payer acceptance, and competition dynamics.
Core market drivers include rising epilepsy prevalence and unmet needs among refractory patients.
Price erosion projections suggest a potential decline to near parity with older epilepsy therapies within five years or sooner.
FAQs
What factors influence the pricing of NDC 78206-0182?
Pricing is driven by manufacturer list prices, reimbursement negotiations, formulary status, and competitive offerings.
How does the market penetration of Xcopri compare to older therapies?
Xcopri currently holds a small share (~4%) in the epilepsy market, mainly due to its recent approval and high cost.
What is the expected timeline for generic competition?
Generic versions could enter the market around 2025–2026, approximately six years post-FDA approval.
How does insurance coverage impact the net price?
Insurance reimbursement often involves rebates and discounts, reducing the net price paid by payers.
What are the implications of price erosion for stakeholders?
Lower prices may expand patient access but could reduce revenue and profitability for the manufacturer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
